Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Cottu

Showing results (71-80 of 140) with videos related to

Pageof 14
Sort By:
Scientific Reports|November 7, 2025
Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie HospitalsAlexandre De Moura, Orane Gleizes, Luc Cabel, et al.
Oncogene|February 27, 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysisAntoine Vasseur, Luc Cabel, Caroline Hego, et al.
Oncotarget|July 25, 2018
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibitionRania El Botty, Florence Coussy, Rana Hatem, et al.
International Journal of Surgical Oncology|February 8, 2012
Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer InstituteAnne Marszalek, Séverine Alran, Suzy Scholl, et al.
Plos One|July 9, 2016
Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Clinical Medicine. Oncology|September 6, 2011
Pre-operative Concomitant Radio-chemotherapy in Bulky Carcinoma of the Cervix: A Single Institution StudyAnne de la Rochefordiere, Youlia Kirova, Severine Alran, et al.
Clinical Chemistry|January 12, 2017
Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast CancerFrancesca Riva, Francois-Clement Bidard, Alexandre Houy, et al.
International Journal of Cancer|August 12, 2023
CANTO skin: Evaluation of skin toxicity risk factors in patients treated for breast cancerSofiane Allali, Matthieu Carton, Sibille Everhard, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
The Challenge of Return to Work after Breast Cancer: The Role of Family Situation, CANTO CohortElsa Caumette, Inès Vaz-Luis, Sandrine Pinto, et al.
Breast Cancer Research : BCR|March 7, 2021
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patientsLauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, et al.
Pageof 14

Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
Scientific Reports|November 7, 2025
Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie HospitalsAlexandre De Moura, Orane Gleizes, Luc Cabel, et al.
Oncogene|February 27, 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysisAntoine Vasseur, Luc Cabel, Caroline Hego, et al.
Oncotarget|July 25, 2018
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibitionRania El Botty, Florence Coussy, Rana Hatem, et al.
International Journal of Surgical Oncology|February 8, 2012
Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer InstituteAnne Marszalek, Séverine Alran, Suzy Scholl, et al.
Plos One|July 9, 2016
Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
Clinical Medicine. Oncology|September 6, 2011
Pre-operative Concomitant Radio-chemotherapy in Bulky Carcinoma of the Cervix: A Single Institution StudyAnne de la Rochefordiere, Youlia Kirova, Severine Alran, et al.
Clinical Chemistry|January 12, 2017
Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast CancerFrancesca Riva, Francois-Clement Bidard, Alexandre Houy, et al.
International Journal of Cancer|August 12, 2023
CANTO skin: Evaluation of skin toxicity risk factors in patients treated for breast cancerSofiane Allali, Matthieu Carton, Sibille Everhard, et al.
Current Oncology (Toronto, Ont.)|October 22, 2021
The Challenge of Return to Work after Breast Cancer: The Role of Family Situation, CANTO CohortElsa Caumette, Inès Vaz-Luis, Sandrine Pinto, et al.
Breast Cancer Research : BCR|March 7, 2021
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patientsLauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, et al.
Pageof 14